BANOVIC, Marko, Bernard IUNG, Jozef BARTUNEK, Milika ASANIN, Branko BELESLIN, Bojan BIOCINA, Filip CASSELMAN, Mark da COSTA, Marek DEJA, Hrvoje GASPAROVIC, Petr KALA, Lois LABROUSSE, Zlatibor LONCAR, Jelena MARINKOVIC, Ivana NEDELJKOVIC, Milan NEDELJKOVIC, Peter NEMEC, Serge D. NIKOLIC, Michael PENCINA, Martin PENICKA, Arsen RISTIC, Faidal SHARIF, Guy Van CAMP, Marc VANDERHEYDEN, Wojtek WOJAKOWSKI and Svetozar PUTNIK. Rationale and design of the Aortic Valve replAcemenT versus conservative treatment in Asymptomatic seveRe aortic stenosis (AVATAR trial): A randomized multicenter controlled event-driven trial. American Heart Journal. New York: Mosby Inc., 2016, vol. 174, "neuvedeno", p. 147-153. ISSN 0002-8703. Available from: https://dx.doi.org/10.1016/j.ahj.2016.02.001.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Rationale and design of the Aortic Valve replAcemenT versus conservative treatment in Asymptomatic seveRe aortic stenosis (AVATAR trial): A randomized multicenter controlled event-driven trial
Authors BANOVIC, Marko (688 Serbia), Bernard IUNG (250 France), Jozef BARTUNEK (56 Belgium), Milika ASANIN (688 Serbia), Branko BELESLIN (688 Serbia), Bojan BIOCINA (688 Serbia), Filip CASSELMAN (56 Belgium), Mark da COSTA (372 Ireland), Marek DEJA (616 Poland), Hrvoje GASPAROVIC (191 Croatia), Petr KALA (203 Czech Republic, guarantor, belonging to the institution), Lois LABROUSSE (250 France), Zlatibor LONCAR (688 Serbia), Jelena MARINKOVIC (688 Serbia), Ivana NEDELJKOVIC (688 Serbia), Milan NEDELJKOVIC (688 Serbia), Peter NEMEC (203 Czech Republic), Serge D. NIKOLIC (840 United States of America), Michael PENCINA (840 United States of America), Martin PENICKA (56 Belgium), Arsen RISTIC (688 Serbia), Faidal SHARIF (372 Ireland), Guy Van CAMP (56 Belgium), Marc VANDERHEYDEN (56 Belgium), Wojtek WOJAKOWSKI (616 Poland) and Svetozar PUTNIK (688 Serbia).
Edition American Heart Journal, New York, Mosby Inc. 2016, 0002-8703.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 4.436
RIV identification code RIV/00216224:14110/16:00092677
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.ahj.2016.02.001
UT WoS 000372538500021
Keywords in English VALVULAR HEART-DISEASE; BEFORE-SYMPTOM-ONSET; HIGH-RISK PATIENTS; NATURAL-HISTORY; CLINICAL-TRIALS; FOLLOW-UP; SURGERY; PATIENT; PROSTHESIS; SURVIVAL
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 10/1/2017 11:10.
Abstract
Aortic valve replacement (AVR) therapy is an obvious choice for symptomatic severe aortic stenosis (AS) patients as it improves symptoms, left ventricular function, and survival. The treatment decisions and indication for AVR in asymptomatic patients with severe AS and normal left ventricular ejection fraction are less well established and the subject of ongoing debate. Many efforts have been made to define the best treatment option in asymptomatic AS patients with normal left ventricular ejection fraction. Retrospective and observational data imply that elective AVR for asymptomatic severe AS may lead to improvement in outcomes in comparison to surgery performed after onset of symptoms. The AVATAR trial will aim to assess outcomes among asymptomatic AS patients randomized to either elective early AVR or medical management with vigilant follow-up. In the latter group, AVR would be delayed until either the onset of symptoms or changes in predefined echocardiographic parameters. To the best of the authors' knowledge, it will be the first large prospective, randomized, controlled, multicenter clinical trial that will evaluate the safety and efficacy of elective AVR in this specific group of patients.
PrintDisplayed: 30/5/2024 17:56